LUCID CAPITAL MARKETS Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.